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ABSTRACT 
Pharmaceuticals escape wastewater treatment plants and contaminate aquatic 
environments; there is increasing concern about the exposure of aquatic organisms 
and the combined toxicity of this complex mixture of chemicals.  Four human 
pharmaceuticals were chosen for this study: all are water-soluble and thus, 
complications of solvent effects are eliminated, and all are commonly used in the U.S. 
and have been detected in the aquatic environment. A 48-hour motility assay of <24 
hour-old Daphnia magna neonates was used to examine the effects of a mixture of 
commonly-used pharmaceuticals. Due to the lack of aquatic toxicity data, LC50 (lethal 
concentration at the 50
th
 percentile) and NOAEL (no observed adverse effect level) 
concentrations of propranolol, metoprolol, terbutaline, and metformin were estimated.  
The first part of this study investigates the acute toxicity of these four drugs – 
two beta blockers, a bronchodilator and an antihyperglycemic drug, respectively – 
using high concentration binary mixtures according to methods well-established in 
the literature. These methods are aimed at establishing the nature of the interactions, 
determining whether the drugs are synergistic (higher toxicity) or antagonistic (lower 
toxicity) when given in combination. The interaction of metformin and metoprolol 
was shown to be antagonistic.  
The second part of this study examines mixture toxicity again, but at low, 
environmentally-relevant concentrations in complex mixtures. Synergism and 
antagonism were observed in these mixtures. In contrast to the results described for 
high-concentration experiments metformin and metoprolol were synergistic. 
Additionally, metformin and metoprolol together (but not separately) were synergistic 
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with propranolol. Terbutaline and propranolol were also synergistic, but the addition 
of either metformin or metoprolol to the mixture antagonized the combined toxicity 
of the terbutaline/propranolol mix. None of these relationships would be predicted by 
the drugs‟ mechanism of action in humans.  
These results suggest that mixture toxicity evaluated at high (LC50) 
concentrations may not predict the interactions observed at low, environmentally-
relevant (NOAEL) concentrations. This calls into question the standard methods for 
evaluating mixture toxicity. Additionally, frequent use of pharmaceuticals by 
consumers coupled with imperfect methods of wastewater treatment will likely 
increase pharmaceutical residue in the aquatic environment. Future experiments will 
be aimed at determining the mechanism of drug interactions observed in this study. 
Furthermore, it should also consider the toxicological impact of degradation products 
of pharmaceutical mixtures on the overall aquatic ecosystem and human health.  
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INTRODUCTION 
Pharmaceuticals and their metabolites enter the aquatic environment from 
leaching, excretion of human waste and through wastewater systems (Kim et al., 
2007; Dussault et al., 2008; Nikolaou et al., 2007). These substances and their 
metabolites have been detected in many countries in surface water, ground water, 
drinking water, seawater, discharge from sewage treatment plants (STP), wastewater 
treatment plants (WWTP), and soil sediments. Some of the drugs resist degradation 
and are found in the environment in their parent, active form (Fent et al., 2006; 
Hernando et al., 2006; Kim et al., 2007). Unaltered or metabolized pharmaceuticals 
are excreted from the patient through urine and feces and end up in the sewage 
system. However, wastewater treatment plants fail to completely degrade all 
pharmaceuticals, leaving the water contaminated with some pharmaceutical drugs 
(Langford, 2009, Dokianakis, 2004). 
With improved medical treatment and rising human population the number of 
prescriptions dispensed per year is also steadily increasing (Huggett et al., 2003A; 
Huggett et al., 2003B; Koplin et al., 2002). This in turn increases the amount of 
pharmaceuticals that ends up in the environment and is an emerging concern. In 2008, 
the total number of drugs ordered or prescribed in the U.S. was 2.3 billion 
(FASTSTATS, 2011). Even if some pharmaceuticals have relatively short 
environmental half-lives they are assumed to be “pseudopersistents” due to their polar 
and non-volatile nature which prevents them from escaping the aquatic realm 
(Hernando et al., 2006). Additionally, the constant input of pharmaceuticals may also 
induce toxic effects even in trace amounts due to high biological activity at the site of 
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action. Studies have shown that some pharmaceuticals which are specifically 
designed for human target receptors have resulted in sublethal toxicity (cancer and 
reproductive damage) in organisms with genetic similarities due to potent interaction 
(Koplin et al., 2002).  
The environmental concentrations of these drugs are usually detected at trace 
levels (ng/L or ppt); recent published literature supports this estimate (Kolpin et al, 
2002; Kolpin et al, 2004; Stackelberg et al., 2007; Pedrouzo et.al., 2008; Gómez et. 
al., 2006; Gibs et al., 2007; Joakim Larsson et al., 2007; Kosonen et al., 2009). 
Although low, these concentrations may be significant enough to induce toxic and 
synergistic effects on aquatic species due to the drugs‟ continual influx and 
persistence in the environment (Hernando et al., 2006; Isidori et al., 2009; Kim et al., 
2007). Additionally, organisms are exposed to a mixture of chemicals in the 
environment. This may result in different combined effects: simple addition of a toxic 
effect (noninteractive or additive action), an effect which is less than the sum of the 
separate constituents (antagonism) and toxic effects which may exceed the total 
additive effects of the separate constituents (synergism) (Otitoloju, 2002). 
Published toxicity data exist for some of the drugs tested; in general, LC50 
values are quite high but are also highly variable depending on experimental 
conditions (Kim et. al, 2007; NOAA, 2006; Park, 2005). However, even the 
comparatively low environmental concentrations may be significant enough to induce 
toxic and synergistic effects on non-target species due the continual influx and 
persistence in the environment (Hernando et al., 2006; Isidori et al., 2008; Kim et al., 
2009). Frequent prescriptions of drugs account for this constant influx. The full extent 
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of the aquatic exposure to these pharmaceuticals is still unknown. LC50 values have 
been published for the pharmaceuticals in this study: propranolol and metoprolol have 
LC50 values for Daphnia magna of 1.6 mg L
-1
 (Dzialowski, 2006) and 64 mg L
-1
 
(Huggett, 2002) respectively.  
 
Types of Common Pharmaceuticals  
Human and veterinary drugs are continuously released into the environment 
from leaching/excretion of human waste, direct disposal, sewage treatment plants 
(STPs), manufacturing processes, animal excreta, and surface runoff (Hernando et al., 
2006; Kim et al., 2009; Dussault et al., 2007).. Many of these drugs resist degradation 
and remain in the environment at trace levels. However, pharmaceuticals constantly 
enter and persist in the environment due to the high use of drugs prescribed in the 
United States. 
 
Studied Pharmaceuticals 
This study focuses on four commonly prescribed, water-soluble 
pharmaceuticals used in the United States: two beta blockers, a bronchodilator and an 
anithyperglycemic drug (shown in Table 1). Beta blockers such as propranolol, 
metoprolol, and nadolol have been detected in European effluent discharges (Ternes, 
1998). More recently the wastewater effluent samples from Texas, New York, and 
Mississippi detected β-adrenergic receptor antagonists at levels as high as 1.9 µg L-1 
(Huggett et al., 2003B). The site of action for beta blockers is on β-adrenergic 
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receptors, a class of receptors vital for the normal function of the sympathetic branch 
of the vertebrate autonomic nervous system (Huggett et al. 2002).  
Metoprolol (structure shown in Figure 1) is a β1 selective andrenoceptor 
blocking agent which is widely used to treat high blood pressure or hypertension. It 
ranks as the #9 most commonly dispensed drug in the United States (Rxlist, 2011). 
Approximately 2% of the metoprolol entering the wastewater treatment stems from 
hospital effluent (Langford et al., 2009). The amount of metoprolol present in sludge 
ranges from 0.026 µg/L to 0.063 µg/L with a mean of 0.039 µg/L (Radjenović et al., 
2009). According to a study conducted by Huggett et al. (2003B), metoprolol was 
detected in
 
wastewater treatment plants with the highest U.S. concentration effluent 
reported at 1.9 µg L
-1
. 
Figure 1: Example of beta blocker - Metoprolol 
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Propranolol (structure shown in Figure 2) is a β adrenergic receptor blocking 
agent which is also used to treat hypertension, angina, post-traumatic stress, and 
reduce the severity and frequency of migraine headaches. More than 50 million 
Americans are diagnosed with hypertension and more than 4 million suffer from 
angina (Huggett et al., 2002). Around 11% of the propranolol entering the wastewater 
treatment comes from hospital effluent; this may cause minor inhibition on the 
performance of nitrite oxidizing bacteria (Langford et al., 2009; Dokianakis et al., 
2004). The propranolol level found in sludge ranged from 0.072 µg/L to 0.54 µg/L 
with a mean of 0.347 µg/L (Radjenović et al., 2009). Furthermore, propranolol was 
detected in
 
wastewater treatment plants with the highest U.S. concentration effluent 
reported at 1.9 µg L
-1
 (Huggett et al., 2003B). 
 
Terbutaline (structure shown in Figure 3) is a β-adrenergic agonist 
bronchodilator which is used to treat asthma, chronic bronchitis, emphysema and 
other respiratory diseases. A study conducted by Làven et al. (2009) detected 
terbutaline in influent and effluent wastewater at a concentration of around < 0.21 
Figure 2: Example of beta blocker - Propranolol 
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µg/L and <0.085 µg/L respectively. Additionally, the study also showed that the 
concentration levels were reduced to <0.12 µg/L in ozone treated effluent and to < 
0.080 µg/L in wastewater passed through MBR (membrane bioreactor). 
 
Metformin (structure shown in Figure 4) is an antihyperglycemic drug which 
has been used to treat non-insulin-dependent (type 2) diabetes for more than 40 years 
(Salpeter et al., 2003). Metformin was detected in U.S. stream samples with a median 
of 0.11 µg/L and a maximum of 0.15 µg/L (Koplin et al., 2002). In the United States, 
metformin ranks as the 17 most commonly dispensed pharmaceutical (Rxlist, 2011).  
 
 
 
Figure 4: Example of antihyperglycemic drug – Metformin 
Figure 3: Example of bronchodilator - Terbutaline 
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Table 1. Pharmaceuticals tested in the current experiment. 
1
Data obtained from Rxlist, 2011 
 
Confounding Factors 
 Organisms and ecosystems are exposed to a mixture of chemicals in the 
environment which may result in different combined toxic effects: simple addition, 
synergism or antagonism. However, the complication of mixture toxicity of 
pharmaceuticals in the environment is still not fully understood (Otitoloju, 2002). 
Additionally, pharmaceuticals may reach the aquatic environment by bypassing the 
STP effluent, thus directly causing bioaccumulation for organisms downstream 
(Dokianakis, 2004). However, there is still a lack of toxicity information on the 
interaction of commonly used pharmaceuticals in the aquatic environment (Koplin et 
al, 2002). 
 
Generic 
Name 
Brand Name Use Mechanism of 
Action 
Extent of Use
1
 
Metformin FORTAMET® 
GLUMETZA® 
 
Diabetic drug Antihyperglycemic 
drug 
# 17 by 
prescriptions 
dispensed 
Metoprolol LOPRESSOR® Treatment of 
cardiovascular 
disease, 
hypertension 
1-sel blocker # 9 by 
prescriptions 
dispensed 
Propranolol INDERAL® Treatment of 
hypertension 
Non-sel -blocker  
Terbutaline TERBUTALINE 
SULFATE 
Bronchodilator  2-agonist  
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Wastewater Treatment Processes 
 Wastewater treatment speeds up the natural process of water purification and 
is one of the most common forms of pollution control in the United States. The two 
main stages in wastewater treatment are primary and secondary treatment. Aerobic 
bacteria can decompose naturally occurring organic matter in the environment. 
However, the biological oxygen demand needed to decompose the waste produced by 
humans would be too high for naturally occurring bacteria without the help of 
wastewater treatment plants. 
The primary wastewater treatment (as shown in Figure 5) starts with a bar 
screening process which removes twigs, rags and other large debris. Next it is passed 
„downstream‟ through a circular grit chamber where the cinders, sand, and small 
stones are spun out. The suspended solids in the wastewater are then allowed to settle 
to the bottom of the sedimentation tanks and the resulting sludge is removed (US 
EPA, 1998; MDC, 2011). 
Biological treatment is used in secondary wastewater treatment (as shown in 
Figure 6) because it is effective on bacteria, contaminants, fungi and protozoa. 
Around 85% of the organic matter in sewage is removed by using the bacteria   
present in the sludge (US EPA, 1998).  
11 
 
 
Figure 5: Primary wastewater treatment (MDC, 2011) 
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Figure 6: Secondary wastewater treatment (MDC, 2011) 
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Testing toxicities of mixtures 
The standard method for evaluating mixture toxicity measures the toxicity of 
binary mixtures at high concentrations (around their LC50s). However, this does not 
represent the „real‟ environment. Thus, pharmaceuticals are also tested in low 
concentration, binary and more complex mixtures. 
 
Analyses of ecotoxicity data 
In this research study, the data obtained from the tests were analyzed with the 
help of a TU (Toxic Unit) model developed by Brown (1968) and Sprague (1970). 
This provides a graphical representation of the results. The number of toxic units 
associated with each of the constituents of the mixture was calculated as shown 
below: 
 
     
                                 
               
 
 
 Where TUA: Toxic Unit of substance A in the mixture.  
 
If the sum of the TU of all the constituents in the mixture is equal to 1 then the 
interactions are additive. If the sum of constituents is less than one the interactions are 
antagonistic and if the sum is greater than 1 the interaction is synergistic.  
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Isobologram representation 
 Sprague (1970) described a method by which the interactions of the 2-
substance mixtures „A‟ and „B‟ could be represented in two dimensions.  The curve is 
a straight line as shown in Figure 7(a) if the effect is additive. However as shown in 
Figure 7(b), if the effect is synergistic, the isobole of the AB mixture is located below 
the additivity isobole (lower left); whereas, if the effect is antagonistic, the isobole of 
the mixture is located above the isobole of additivity (Otitoloju, 2002; Warne, 2003). 
 
 
 
 
Figure 7: Example of isoboles (a) showing additivity and the domains of antagonism 
and synergism, (b) highlighting a variation of interactions between two substances as 
a function of their ratio (Warne, 2003). 
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In the current study, five different mixture ratios of each binary pair were 
prepared (20:80, 40:60, 50:50, 60:40, and 80:20). Each of these mixture ratios was 
tested in triplicate using six different concentrations around the mixture LC50 
according to the method outlined by Panouillères et al. (2007). For the data analysis 
of these mixture experiments, a two-step process was used: the concentration-
response relationships were determined and an isobole analysis was used to assess the 
interaction of the two drugs in the mixture.  
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RESEARCH OBJECTIVE 
This research study compares the results from testing mixtures in two ways: 
1) High concentration, binary mixtures 
2) Low concentration, binary and more complex mixtures 
 
High concentration, binary mixtures 
The first part of the study analyzes the effects of commonly used 
pharmaceuticals in binary mixtures on Daphnia magna.  First, the LC50 will be 
determined for each drug on Daphnia magna.  Subsequently, mixtures of 
pharmaceuticals will be used to assess possible synergism and antagonism using 
methods well-established in the literature.  
 
Low Concentration, binary and more complex mixtures 
The second part of the study seeks to better understand mixture toxicity at 
environmentally relevant concentrations. It is possible that interactions at low 
environmentally relevant concentrations will be different that those at high 
concentrations. This would call into question the standard methods used to assess 
mixture toxicity. However, there is limited information available on the toxicological 
effects of pharmaceuticals in the environment and it is vital to continue research to 
understand these interactions in greater depth. 
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MATERIALS AND METHODS 
Stock solutions of 100g/L were prepared in hard water and stored at 4° C until used. 
Lower concentrations were prepared by serial dilution. 
o β1 selective andrenoceptor blocking agent: Metoprolol (Sigma-Aldrich) 
o β-adrenergic receptor blocking agent: Propranolol (Sigma-Aldrich) 
o β-adrenergic agonist bronchodilator: Terbutaline (Sigma-Aldrich) 
o Antihyperglycemic drug: Metformin (Sigma-Aldrich) 
 
Daphnia magna  
Daphnia magna were obtained from Aquatic Research Organisms (Hampton, 
NH). Acute toxicity tests were performed in hard water according to Standard 
Methods (1998). Ten neonates (<24 hr old) were placed in test tubes with 10 mL of 
drug solution prepared in hard water. Daphnia were incubated at room temperature 
and the motile daphnia were counted after 48 hrs. Each of the tests was performed in 
triplicate. 
 
Determination of LC50 values  
Incubations were performed as described above, using 5 concentrations 
around the LC50 value. For Daphnia Magna, 48-hr LC50 values for the 24-hr old 
larvae were determined by probit analysis.  
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Determination of NOAEL (No Observed Adverse Effect Level)  
For each drug that was used in this study the NOAEL (the highest 
concentration tested that causes no toxicity) was determined.  
 
Preparation of Hard Water 
Hard water was prepared according to the Standard Methods (Eaton, 1998).  
To prepare 4 L of hard water using DDI (distilled deionized water), the following 
amounts of salts (as shown in Table 2) were used:  
 
Table 2.  Amount of salt (by weight) needed to make 4 L of hard water 
Salt Formula 4L 
Sodium bicarbonate NaHCO3 0.768 g 
Calcium sulfate dehydrate CaSO4 • 2H2O 0.480 g 
Magnesium sulfate heptahydrate MgSO4 • 7H2O 0.737 g 
Potassium chloride KCl 0.032 g 
 
The salts were added to distilled deionized water in a glass Erlenmeryer flask 
with a stir bar and then placed on a magnetic stir plate for at least 48 hours before 
experiments. Water was aerated by bubbling air through in order to equilibrate the 
carbonate buffer. 
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RESULTS AND DISCUSSION 
 This study exposed the test organism, Daphnia magna, to varying 
concentrations of commonly used pharmaceuticals to assess the toxicity of 
pharmaceuticals in the environment. The pharmaceuticals were tested in high 
concentration binary mixtures and at low concentration for binary and more complex 
mixtures. 
 
LC50 Value Determination 
The LC50 value was experimentally determined for each drug due to the lack 
of information available on the aquatic toxicity of these pharmaceuticals to Daphnia 
magna and to determine concentrations needed for mixture experiments. The LC50 
values determined for metformin, metoprolol and propranolol were 87.5 ppm, 175 
ppm and 3.9 ppm respectively. These LC50 concentrations were used in subsequent 
high-concentration mixture toxicity experiments.  
 
High-concentration Mixture Toxicity  
Three binary mixtures BC, BD and CD were tested, where B = Metformin, C 
= Metoprolol and D = propranolol. The isobole parameters for the binary mixtures 
tested with Daphnia magna are shown below.  
If Figure 8 is compared to Figure 7 (b) the results indicate that the interaction 
between high concentration binary mixture of metformin and metoprolol is 
antagonistic (it lies above the line of additivity).  
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Figure 8: Isobolic representation of estimated dose combination for binary mixture of B = 
Metformin, C = Metoprolol, TU = Toxic Unit, tested with Daphnia magna. 
Figure 9: Isobolic representation of estimated dose combination for binary mixture of 
B = Metformin, D = Propranolol, TU = Toxic Unit, tested with Daphnia magna. 
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Both Figure 9 and Figure 10 show the isobolic representation for binary 
mixtures of BD (metformin, propranolol) and CD (metoprolol, propranolol). A line of 
additivity is not observed in these two figures. A possible reason for this could be that 
propranolol is very potent and its presence in the mixture overshadows the TU (Toxic 
Unit) for the other substance. Future work with terbutaline, which has an LC50 around 
the same order of magnitude as metoprolol and metformin will be helpful in 
elucidating additional interactions and addressing this hypothesis.  
  
Figure 10: Isobolic representation of estimated dose combination for binary mixture of 
C = Metoprolol, D = Propranolol, TU = Toxic Unit, tested with Daphnia magna. 
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NOAEL Tests 
  The NOAEL tests were performed first on all four pharmaceuticals to 
determine the concentration at which the average percentage survival for Daphnia 
magna was around 100%. The results of the test determined the NOAEL levels for 
each drug as follows: terbutaline (100 ppm), metformin (50 ppm), metoprolol (50 
ppm) and propranolol (1 ppm). 
 
Low-concentration Mixtures 
 Daphnia neonates were incubated for 48 hours at room temperature with the 
simple and complex mixtures and survival was recorded to assess toxicity. As shown 
in Figure 11, almost all of the neonates survived at the NOAEL concentrations with 
around 100% survival. However, when metformin and metoprolol were added to 
terbutaline, a synergistic effect was observed and the average percentage of survival 
decreased to around 56%. Furthermore, adding propranolol to this mixture lowered 
the survival rate of Daphnia magna even more to around 25%. A similar synergistic 
effect was seen when metoprolol and propranolol were added to metformin where the 
average survival percentage decreased to around 38%.   
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Figure 11:  Synergystic effect of Terbutaline (100 ppm), Metformin (50 ppm), Metoprolol(50 
ppm) and Propranolol(1 ppm) mixtures on survival of  24 hour neonate Daphnia magna in a 48 
hour exposure.  
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Figure 12: Synergistic effect of Terbutaline (100 ppm), Metformin (50 ppm), 
Metoprolol (50 ppm) and Propranolol (1 ppm) mixtures on survival of 24 hour 
neonate Daphnia magna in a 48 hour exposure. 
 
 Mixtures where metformin and metoprolol occurred together (but not 
individually) with propranolol demonstrated synergistic effects (see Figure 12 and 
Figure 13).  Terbutaline and propranolol were also synergistic; however, the addition 
of either metformin or metoprolol to the mixture antagonized the combined toxicity 
(see Figure 12 and Figure 14). In the mixture of all four drugs, the synergistic effect 
observed was of the highest magnitude and the average survival percentage dropped 
from 100% in control to around 23%. 
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Figure 13: Synergistic effect of Metformin (50 ppm), Metoprolol (50 ppm) and Propranolol (1 
ppm) mixtures on survival of 24 hour neonate Daphnia magna in a 48 hour exposure.  
 
Figure 14: Synergistic effect of Terbutaline (100 ppm), Metformin (50 ppm) and Metoprolol (50 
ppm) mixtures on survival of 24 hour neonate Daphnia magna in a 48 hour exposure. 
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In contrast to Figure 8, the low concentration complex mixture exposure (see 
Figure 13) suggests that the interaction of metformin and metoprolol at 
environmentally relevant concentrations is synergistic. This underscores an important 
point: the standard method for assessing mixture toxicity, using high concentrations 
of binary mixtures, does not accurately represent the „real‟ environment. The 
interaction between chemicals in a mixture may be completely different at low, 
environmentally-relevant concentrations.   
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CONCLUSION 
The differing metoprolol-metformin interactions shown in this study for high 
concentration and low concentration mixtures suggests that perhaps studying 
environmentally relevant exposures may be a more accurate representation of what 
happens in the aquatic environment. Future work will be aimed at testing additional 
drugs in binary and more complex mixtures to further elucidate this conclusion. 
Toxicity endpoints other than mortality, including changes to growth and 
development, may occur at concentrations lower than LC50 values, or if chronic 
exposure occurs. In the experiments each drug was incubated at the NOAEL 
concentration: terbutaline (100 ppm), metformin (50 ppm), metoprolol (50 ppm) and 
propranolol (1 ppm). Synergism was observed in many of the mixtures, as shown 
above. 
Additionally, further experiments need to be conducted with more complex 
mixture combinations using different concentrations and future studies should be 
directed towards elucidating the mechanisms of the observed toxicity and drug-drug 
interactions. Additional studies should also consider the toxicological impact of 
degradation products of drugs on aquatic life, the impact of drugs on other organisms 
and on the complete aquatic ecosystem. Future studies could also focus on utilizing 
better analytical techniques to reduce the experimental error and get more accurate 
and precise results. Furthermore, some pharmaceuticals target a specific biochemical 
site of action and the toxic effects observed may differ based on the sensitivity of the 
organism. Subsequently, pharmaceuticals may not be harmful to particular organisms; 
however, it may cause sub-lethal toxicity in organisms with genetic similarities. Thus, 
28 
 
future studies could assess synergism and antagonism in toxicity of mixtures of 
pharmaceuticals on other aquatic organisms. 
Due to the persistence and increasing use of pharmaceuticals, they are 
increasingly more likely to be an environmental concern. Thus the research done in 
this field could form the foundation for better environmental regulation for 
pharmaceuticals in the wastewater and aquatic environment, particularly taking 
mixture effects into account.  
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